An investigation on behalf of investors, who currently hold shares of Envision Healthcare Corporation (NYSE: EVHC), was announced concerning whether the takeover of Envision Healthcare. by KKR is unfair to NYSE: EVHC stockholders.

The investigation by a law firm concerns whether certain officers and directors of Envision Healthcare Corporation breached their fiduciary duties owed to NYSE: EVHC investors in connection with the proposed acquisition.

On June 11, 2018, Envision Healthcare Corporation (NYSE: EVHC) announced it has entered into a agreement to be acquired by global investment firm KKR in an all-cash transaction for approximately $9.9 billion, including the assumption or repayment of debt. Under the terms of the agreement, KKR will acquire all of the outstanding shares of Envisions common stock for $46.00 per share in cash.

However, given that at least one analyst has set the high target price for NYSE: EVHC shares at $51.00 per share and given that NYSE: EVHC shares traded in 2017 as high as $82.78 per share, the investigation concerns whether the offer is unfair to NYSE: EVHC stockholders. More specifically, the investigation concerns whether the Envision Healthcare Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Envision Healthcare Corporation reported that its annual Total Revenue rose from over $3.49 billion in 2016 to over $7.81 billion in 2017.

On June 19, 2018, NYSE: EVHC shares closed at $44.70 per share.